By Counterforce Health Team in Cimzia (certolizumab pegol) —

How to Get Cimzia (Certolizumab Pegol) Covered by Aetna in Florida: Complete PA Guide with Forms and Appeals

Answer Box: Getting Cimzia Covered by Aetna in Florida

Aetna requires prior authorization for Cimzia (certolizumab pegol) in Florida across all plan types. The fastest path to approval: (1) Download the Aetna Cimzia precertification form, (2) Document failed conventional therapies (methotrexate for RA, NSAIDs for AS), and (3) Include TB/hepatitis B screening within 12 months. Submit via Availity portal or fax to the address on your denial letter. Standard decisions take 30 days; expedited appeals for urgent cases get 72-hour decisions. If denied, you have 180 days to appeal internally before pursuing Florida's external review process.

Table of Contents

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all Aetna plans Precert forms vary by plan type Aetna PA List
Formulary Status Typically non-preferred (higher copay) Plan-specific drug lists CVS Caremark
Step Therapy Must try conventional therapies first Varies by indication Aetna Clinical Policy
TB Screening Required within 12 months PPD/IGRA + chest X-ray FDA Label
Specialist Prescriber Rheumatologist, GI, or dermatologist Varies by condition Aetna Policy

Step-by-Step: Fastest Path to Approval

1. Verify Your Aetna Plan Type

Who: Patient or clinic staff
Document needed: Insurance card
Action: Call member services (1-800-AETNA-US) to confirm formulary status and PA requirements
Timeline: 5-10 minutes

2. Download the Correct PA Form

Who: Prescriber's office
Document needed: Commercial PA form or Medicare Part B form
Action: Complete all sections with clinical rationale
Timeline: 30-45 minutes

3. Gather Required Screening Results

Who: Prescriber
Documents needed: TB screening (PPD/IGRA), hepatitis B panel, chest X-ray
Action: Order tests if not current within 12 months
Timeline: 1-3 days for results

4. Document Prior Treatment Failures

Who: Prescriber
Documents needed: Chart notes showing inadequate response to conventional therapies
Action: Include specific drugs, doses, duration, and reasons for discontinuation
Timeline: Chart review (15-30 minutes)

5. Submit PA Request

Who: Clinic staff
Submission method: Availity portal (preferred) or fax to number on form
Required attachments: Completed form, chart notes, lab results
Timeline: Same day submission

6. Track Your Request

Who: Patient or clinic
Action: Follow up if no response in 5 business days
Contact: Provider line 1-800-624-0756
Timeline: Standard decisions within 30 days

7. Appeal if Denied

Who: Patient or provider
Deadline: 180 days from denial notice
Action: Submit additional clinical evidence addressing denial reasons
Timeline: 30 days for internal appeal decision

Tip: Expedited reviews are available if delay would seriously jeopardize your health. Mark requests "EXPEDITED" and include physician justification for 72-hour decisions.

Medical Necessity Criteria by Condition

Rheumatoid Arthritis (Moderately to Severely Active)

  • Disease activity: DAS28 >5.1 or equivalent measures
  • Prior therapy failure: Inadequate response to methotrexate, leflunomide, or sulfasalazine at adequate doses
  • Duration: Minimum 3-month trial of conventional DMARD
  • Documentation: Joint counts, inflammatory markers (CRP/ESR), functional assessment

Crohn's Disease (Moderate to Severe)

  • Disease severity: CDAI >220 or equivalent clinical assessment
  • Prior therapy: Inadequate response to conventional treatments (corticosteroids, immunomodulators)
  • Specialist requirement: Must be prescribed by gastroenterologist
  • Monitoring: Objective measures of disease activity (endoscopy, biomarkers)

Psoriatic Arthritis (Active)

  • Joint involvement: Active arthritis with inadequate response to conventional therapy
  • Prior treatments: Failure of methotrexate or other DMARDs
  • Specialist prescriber: Rheumatologist or dermatologist
  • Assessment: Joint counts, skin involvement (PASI if applicable)

Ankylosing Spondylitis (Active)

  • Symptoms: Active axial symptoms with inadequate response to NSAIDs
  • Prior therapy: Failure of at least 2 NSAIDs (or contraindication/intolerance)
  • Duration: Minimum 4-week trials of NSAIDs at adequate doses
  • Assessment: BASDAI, spinal mobility measures, inflammatory markers

Required Documentation

Universal Requirements (All Indications)

  • TB screening: PPD ≥5mm or positive IGRA within 12 months
  • Hepatitis B panel: HBsAg, anti-HBs, anti-HBc within 12 months
  • Complete blood count: Within 3 months
  • Liver function tests: Within 3 months
  • Specialist consultation: Appropriate subspecialist evaluation

Condition-Specific Evidence

  • Chart notes: Detailed clinical assessment with objective measures
  • Prior treatment records: Medications tried, doses, duration, response, reasons for discontinuation
  • Laboratory results: Disease-specific markers (RF, anti-CCP for RA; CRP/ESR for inflammatory conditions)
  • Imaging: When relevant (joint X-rays for RA/PsA, MRI for axSpA)
Clinician Corner: When writing medical necessity letters, structure your argument around Aetna's published criteria. Include: (1) specific diagnosis with ICD-10 code, (2) objective disease activity measures, (3) detailed prior treatment history with outcomes, (4) clinical rationale for Cimzia over alternatives, and (5) monitoring plan.

Appeals Process in Florida

Internal Appeals Timeline

  • Filing deadline: 180 days from denial notice (members) or 90 days (providers)
  • Standard review: 30 days for decision
  • Expedited review: 72 hours for urgent cases
  • Submission: Use denial letter address or Aetna provider portal

Required Appeal Documents

  • Original denial letter
  • Additional clinical evidence addressing denial reasons
  • Letter of medical necessity from prescribing physician
  • Updated lab results or imaging if relevant
  • Peer-reviewed literature supporting off-label use (if applicable)

External Review (After Internal Appeals)

  • Eligibility: Must exhaust Aetna's internal appeal levels
  • Deadline: 120 days after final internal denial
  • Process: File complaint with Florida Department of Financial Services
  • Cost: Free to consumers
  • Timeline: 30-60 days for decision
  • Binding: Yes, if reviewer finds in your favor
Note: For ERISA plans (employer-sponsored), external review follows federal rather than Florida state processes.

Common Denial Reasons & Solutions

Denial Reason Solution Required Documentation
"Not medically necessary" Submit detailed clinical rationale with objective measures Disease activity scores, failed treatments, specialist letter
"Step therapy not met" Document prior treatment failures or request exception Chart notes with specific drugs, doses, duration, outcomes
"Experimental/investigational" Cite FDA approval and clinical guidelines FDA label, specialty society recommendations
"Missing TB screening" Provide current screening results PPD/IGRA within 12 months, chest X-ray
"Quantity limits exceeded" Justify dosing based on FDA labeling Prescriber letter explaining dosing rationale

Sample Appeal Language

"Patient has moderate-to-severe rheumatoid arthritis (ICD-10: M06.9) with DAS28 of 6.2 despite adequate trials of methotrexate 25mg weekly for 4 months and leflunomide 20mg daily for 3 months. Both medications were discontinued due to inadequate efficacy (persistent joint swelling and morning stiffness >2 hours). Current CRP is elevated at 8.2 mg/L. Cimzia is FDA-approved for this indication and medically necessary per Aetna's published criteria."

Cost Savings Programs

Manufacturer Support

  • Cimzia Complete: Patient support program offering copay assistance up to $25,000 annually
  • Eligibility: Commercial insurance (not Medicare/Medicaid)
  • Application: CimziaComplete.com or 1-866-4CIMZIA

Foundation Assistance

  • Patient Advocate Foundation: Copay relief for qualifying patients
  • Good Days: Chronic disease fund for specialty medications
  • HealthWell Foundation: Financial assistance based on diagnosis and income

State Programs

  • Florida Medicaid: May cover Cimzia with PA approval
  • Pharmaceutical assistance programs: Check eligibility through Benefits.gov

At Counterforce Health, we help patients navigate complex prior authorization requirements by analyzing denial letters and crafting evidence-backed appeals. Our platform identifies the specific denial basis and generates targeted rebuttals aligned with each payer's own criteria, significantly improving approval rates for specialty medications like Cimzia.

Frequently Asked Questions

How long does Aetna PA take for Cimzia in Florida?
Standard prior authorization decisions are made within 30 days. Expedited reviews for urgent medical situations are decided within 72 hours.

What if Cimzia isn't on my Aetna formulary?
You can request a formulary exception by providing clinical justification for why preferred alternatives aren't appropriate. This requires additional documentation of contraindications or prior failures.

Can I get expedited approval if I'm currently on Cimzia?
Yes, if you're already responding well to Cimzia and switching would be medically inappropriate, mark your request as expedited and include physician documentation of medical urgency.

Does step therapy apply if I failed anti-TNF drugs outside Florida?
Yes, documented failures of preferred therapies from any location count toward step therapy requirements. Ensure your new Florida provider has complete treatment records.

What happens if Aetna denies my appeal?
After exhausting internal appeals, you can request external review through Florida's Department of Financial Services. This independent review is free and binding if decided in your favor.

How much does Cimzia cost without insurance?
The list price is approximately $6,000 for a two-syringe maintenance pack. Patient assistance programs can significantly reduce out-of-pocket costs for eligible individuals.

Can my doctor request a peer-to-peer review?
Yes, physicians can request to speak directly with Aetna's medical director to discuss the clinical rationale for Cimzia. This often helps resolve complex cases.

What if I need Cimzia for an off-label use?
Off-label uses require additional documentation including peer-reviewed literature, specialty society guidelines, and detailed clinical rationale. Recognized drug compendia citations strengthen these requests.

Sources & Further Reading:

This information is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan benefits and clinical circumstances. Always consult with your healthcare provider and insurance company for personalized guidance. For assistance with insurance complaints in Florida, contact the Department of Financial Services at 1-877-MY-FL-CFO.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.